RU2004122702A - Способы получения полиспецифичных, поливалентных средств из vh и vl доменов - Google Patents
Способы получения полиспецифичных, поливалентных средств из vh и vl доменов Download PDFInfo
- Publication number
- RU2004122702A RU2004122702A RU2004122702/13A RU2004122702A RU2004122702A RU 2004122702 A RU2004122702 A RU 2004122702A RU 2004122702/13 A RU2004122702/13 A RU 2004122702/13A RU 2004122702 A RU2004122702 A RU 2004122702A RU 2004122702 A RU2004122702 A RU 2004122702A
- Authority
- RU
- Russia
- Prior art keywords
- binding protein
- binding
- linker
- polypeptide
- polypeptides
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 11
- 102000023732 binding proteins Human genes 0.000 claims 46
- 108091008324 binding proteins Proteins 0.000 claims 46
- 238000009739 binding Methods 0.000 claims 34
- 229920001184 polypeptide Polymers 0.000 claims 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims 29
- 239000003814 drug Substances 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 10
- 239000002299 complementary DNA Substances 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 239000013612 plasmid Substances 0.000 claims 6
- 239000002872 contrast media Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 claims 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 239000000032 diagnostic agent Substances 0.000 claims 4
- 229940039227 diagnostic agent Drugs 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 229910052751 metal Inorganic materials 0.000 claims 4
- 239000002184 metal Substances 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 238000006073 displacement reaction Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000002739 metals Chemical class 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 229910052688 Gadolinium Inorganic materials 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 1
- 239000013522 chelant Substances 0.000 claims 1
- 150000004697 chelate complex Chemical class 0.000 claims 1
- 238000002591 computed tomography Methods 0.000 claims 1
- 239000000562 conjugate Substances 0.000 claims 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34210301P | 2001-12-26 | 2001-12-26 | |
| US60/342,103 | 2001-12-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004122702A true RU2004122702A (ru) | 2005-04-20 |
Family
ID=23340336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004122702/13A RU2004122702A (ru) | 2001-12-26 | 2002-12-26 | Способы получения полиспецифичных, поливалентных средств из vh и vl доменов |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20030162709A1 (enExample) |
| EP (1) | EP1468097A4 (enExample) |
| JP (1) | JP2005514030A (enExample) |
| KR (1) | KR20040091616A (enExample) |
| AU (1) | AU2002364531A1 (enExample) |
| BR (1) | BR0215403A (enExample) |
| CA (1) | CA2471868A1 (enExample) |
| IL (1) | IL162732A0 (enExample) |
| MX (1) | MXPA04006327A (enExample) |
| PL (1) | PL372144A1 (enExample) |
| RU (1) | RU2004122702A (enExample) |
| WO (1) | WO2003057829A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6962702B2 (en) * | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| CN1604910A (zh) * | 2001-10-15 | 2005-04-06 | 免疫医疗公司 | 亲和性增强物质 |
| US8435529B2 (en) | 2002-06-14 | 2013-05-07 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
| ES2871905T3 (es) | 2002-03-01 | 2021-11-02 | Immunomedics Inc | Inmunoconjugado que comprende anticuerpos de RS7 humanizados |
| US9770517B2 (en) | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
| US20040022726A1 (en) * | 2002-06-03 | 2004-02-05 | Goldenberg David M. | Methods and compositions for intravesical therapy of bladder cancer |
| EP1587550B1 (en) * | 2003-01-31 | 2011-07-27 | Immunomedics, Inc. | Methods and compositions for administering therapeutic and diagnostic agents |
| EP1618181B1 (en) * | 2003-04-22 | 2014-10-15 | IBC Pharmaceuticals | Polyvalent protein complex |
| CN1326881C (zh) * | 2003-09-29 | 2007-07-18 | 中国人民解放军军事医学科学院基础医学研究所 | 一种三价双特异性抗体，其制备方法及用途 |
| US20060057062A1 (en) * | 2004-09-10 | 2006-03-16 | Trotter Dinko G | Compositions and methods useful in pretargeted imaging |
| EP3332808B1 (en) | 2005-03-03 | 2020-09-09 | Immunomedics Inc. | Humanized l243 antibodies |
| US9339559B2 (en) | 2005-09-09 | 2016-05-17 | Georgia State University Research Foundation, Inc. | Targeted contrast agents and methods for targeting contrast agents |
| HUE026303T2 (hu) | 2005-07-25 | 2016-06-28 | Emergent Product Dev Seattle | B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával |
| WO2007030802A2 (en) * | 2005-09-09 | 2007-03-15 | Georgia State University Research Foundation, Inc. | Targeted contrast agents and methods for targeting contrast agents |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| PT2500360E (pt) | 2005-10-31 | 2015-10-15 | Oncomed Pharm Inc | Composições e métodos para diagnóstico e tratamento do cancro |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| EP2518155B1 (en) | 2006-08-04 | 2014-07-23 | Georgia State University Research Foundation, Inc. | Enzyme sensors, methods for preparing and using such sensors, and methods of detecting protease activity |
| CA2671431C (en) | 2006-12-14 | 2019-03-26 | Georgia State University Research Foundation, Inc. | Analyte sensors, methods for preparing and using such sensors, and methods of detecting analyte activity |
| WO2009146099A2 (en) | 2008-04-02 | 2009-12-03 | Georgia State University Research Foundation, Inc. | Contrast agents, methods for preparing contrast agents, and methods of imaging |
| AU2009234277B2 (en) | 2008-04-11 | 2014-12-04 | Aptevo Research And Development Llc | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| MX2011003183A (es) | 2008-09-26 | 2011-04-21 | Oncomed Pharm Inc | Agentes que se unen a receptor encrespado y usos de los mismos. |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| KR20130043102A (ko) | 2010-04-01 | 2013-04-29 | 온코메드 파마슈티칼스, 인크. | 프리즐드-결합 작용제 및 그의 용도 |
| WO2013184786A2 (en) * | 2012-06-05 | 2013-12-12 | Georgia State University Research Foundation, Inc. | Contrast agents, methods for preparing contrast agents, and methods of imaging |
| US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
| HK1212216A1 (en) | 2012-10-23 | 2016-06-10 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using wnt pathway-binding agents |
| HK1211887A1 (en) | 2013-02-04 | 2016-06-03 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a wnt pathway inhibitor |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| EP2930188A1 (en) * | 2014-04-13 | 2015-10-14 | Affimed Therapeutics AG | Trifunctional antigen-binding molecule |
| CA2981543A1 (en) | 2015-04-22 | 2016-10-27 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| EP3156417A1 (en) * | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalent fv antibodies |
| US11571476B2 (en) | 2017-12-11 | 2023-02-07 | Taipei Medical University | Anti-tumor/anti-tumor associated fibroblast/anti-hapten trispecific antibodies and use thereof |
| TWI870708B (zh) * | 2017-12-12 | 2025-01-21 | 臺北醫學大學 | 多特異性抗體及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0088994B1 (en) * | 1982-03-15 | 1991-06-19 | Schering Corporation | Hybrid dna, binding composition prepared thereby and processes therefor |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| FR2604092B1 (fr) * | 1986-09-19 | 1990-04-13 | Immunotech Sa | Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo |
| US5132405A (en) * | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6027725A (en) * | 1991-11-25 | 2000-02-22 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US6096289A (en) * | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
| WO1994007921A1 (en) * | 1992-09-25 | 1994-04-14 | Commonwealth Scientific And Industrial Research Organisation | Target binding polypeptide |
| EP0672142B1 (en) * | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| BR9606706A (pt) * | 1995-10-16 | 1999-04-06 | Unilever Nv | Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo |
| CA2249320C (en) * | 1996-03-20 | 2008-12-23 | Immunomedics, Inc. | Glycosylated humanized b-cell specific antibodies |
| ES2225961T3 (es) * | 1996-04-04 | 2005-03-16 | Unilever N.V. | Proteina de union a antigeno multivalente y multiespecifica. |
| US6183744B1 (en) * | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| JP4113670B2 (ja) * | 1998-06-22 | 2008-07-09 | イムノメディクス， インコーポレイテッド | プレターゲッティング診断およびプレターゲッティング治療のための二重特異性抗体の使用 |
-
2002
- 2002-12-26 US US10/328,190 patent/US20030162709A1/en not_active Abandoned
- 2002-12-26 CA CA002471868A patent/CA2471868A1/en not_active Abandoned
- 2002-12-26 MX MXPA04006327A patent/MXPA04006327A/es not_active Application Discontinuation
- 2002-12-26 WO PCT/US2002/038985 patent/WO2003057829A2/en not_active Ceased
- 2002-12-26 IL IL16273202A patent/IL162732A0/xx unknown
- 2002-12-26 EP EP02799908A patent/EP1468097A4/en not_active Withdrawn
- 2002-12-26 BR BR0215403-0A patent/BR0215403A/pt not_active IP Right Cessation
- 2002-12-26 AU AU2002364531A patent/AU2002364531A1/en not_active Abandoned
- 2002-12-26 RU RU2004122702/13A patent/RU2004122702A/ru not_active Application Discontinuation
- 2002-12-26 KR KR10-2004-7010211A patent/KR20040091616A/ko not_active Withdrawn
- 2002-12-26 JP JP2003558131A patent/JP2005514030A/ja not_active Withdrawn
- 2002-12-26 PL PL02372144A patent/PL372144A1/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040091616A (ko) | 2004-10-28 |
| MXPA04006327A (es) | 2005-07-13 |
| AU2002364531A1 (en) | 2003-07-24 |
| US20030162709A1 (en) | 2003-08-28 |
| WO2003057829A2 (en) | 2003-07-17 |
| WO2003057829A3 (en) | 2004-02-26 |
| CA2471868A1 (en) | 2003-07-17 |
| EP1468097A4 (en) | 2006-01-11 |
| PL372144A1 (en) | 2005-07-11 |
| JP2005514030A (ja) | 2005-05-19 |
| BR0215403A (pt) | 2005-05-03 |
| IL162732A0 (en) | 2005-11-20 |
| EP1468097A2 (en) | 2004-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004122702A (ru) | Способы получения полиспецифичных, поливалентных средств из vh и vl доменов | |
| JP7027480B2 (ja) | 生物学的製剤の１８ｆ－放射性標識方法および組成物 | |
| JP2005514030A5 (enExample) | ||
| US6010861A (en) | Target specific screens and their use for discovering small organic molecular pharmacophores | |
| EP1546203B1 (en) | Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof | |
| Levchenko et al. | Evaluation of 11C-colchicine for PET imaging of multiple drug resistance | |
| CN101903402A (zh) | 抗tl1a的人源化抗体 | |
| EP3322716B1 (en) | Il-17f-specific capture agents and methods of using | |
| JP2009531324A5 (enExample) | ||
| WO2017176769A1 (en) | Cd8-specific capture agents, compositions, and methods of using and making | |
| Ahlgren et al. | Radionuclide molecular imaging using Affibody molecules | |
| Mitran et al. | Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model | |
| Signore et al. | The developing role of cytokines for imaging inflammation and infection | |
| Balhorn et al. | Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: initial application to lymphoma/leukemia | |
| CN116173250A (zh) | 一种基于核酸适体的靶向分子探针及其制备方法和应用 | |
| CN101796073A (zh) | 针对cxcr3的人源化抗体 | |
| RU2004114878A (ru) | Агенты, увеличивающие аффинность | |
| JP2005518344A5 (enExample) | ||
| Zhang et al. | Imaging the alternatively spliced d domain of tenascin c in a preclinical model of inflammatory bowel disease | |
| DeNARDO et al. | Phage library-derived human anti-TETA and anti-DOTA ScFv for pretargeting RIT | |
| CN111247249B (zh) | Dna、多肽、抗间皮素抗体、肿瘤成像剂和复合体 | |
| US7112410B1 (en) | Human tumor necrosis factor TR21 and methods based thereon | |
| CA2719550A1 (en) | Methods and kits for diagnosing and treating acute joint injury | |
| Sheng et al. | Applications of Nanobodies in Biological Imaging | |
| HK40081578A (en) | Il-17f-specific capture agents, compositions, and methods of using and making |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20060713 |